Breast Cancer Trial, Not Yet Recruiting NCT07187752 Sponsor: Shandong Cancer Hospital and Institute Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT07187752
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 to 75 years.
  • People with a good general health and activity level, rated 0 or 1 on a standard oncology performance scale (ECOG).
  • People with a laboratory-confirmed invasive breast cancer where the primary tumour is larger than 2 centimetres, and the cancer is either early-stage or locally advanced (but not spread to distant parts of the body).
  • People whose breast cancer tests positive for HER2, confirmed by standard laboratory methods.
  • People whose breast cancer has been tested for estrogen receptor (ER) and progesterone receptor (PgR) status, with results available.
  • People whose bone marrow, kidneys, liver, and blood clotting are all functioning at adequate levels.
  • People whose heart pumping function (left ventricular ejection fraction) is 50% or above.
  • Women who could become pregnant, and men whose partners could become pregnant, who agree to use highly effective contraception or avoid intercourse during the study and for at least 7 months after the last dose — and women who have a negative pregnancy test within 7 days before enrolling.
  • People who are willing to provide tissue samples for research purposes.
  • People who voluntarily agree to participate and sign the informed consent form.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose breast cancer has spread to distant parts of the body (stage IV metastatic breast cancer).
  • People who have invasive breast cancer in both breasts at the same time.
  • People who have previously received any anti-cancer treatment for their breast cancer.
  • People who have had another cancer diagnosis within the past 5 years — though people who had another cancer treated with surgery alone and have been disease-free for 5 continuous years, or who have had certain cured, limited cancers such as cervical carcinoma in situ, non-melanoma skin cancer, or certain superficial bladder tumours, may still be considered (confirm with trial site).
  • People who have taken part in another clinical trial of an anti-cancer drug within the 4 weeks before joining this trial.
  • People with uncontrolled or significant heart or cardiovascular disease.
  • People with a known allergy to any of the study drugs or their ingredients.
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • People with any other condition that the trial investigators consider makes participation inappropriate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 13793187739

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Shandong Cancer Hospital and Institute
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
31 December 2026

Primary endpoints

Total pathological complete response (tpCR) rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov